XEMPERIA is a Swiss biotech startup founded in 2023 as a spin-off from the University of Fribourg, aiming to revolutionize cancer care through innovative blood tests. Leveraging over 25 years of expertise in translational cancer research and biomarker discovery, the company focuses on early detection and monitoring of cancer by identifying cancer-associated biomarkers in the blood using advanced multiomics and AI methodologies.

Their flagship project is a blood test for the early detection of breast cancer, which has successfully completed an initial phase of clinical validation. XEMPERIA is now preparing for a large-scale performance study, with the goal of achieving certification and commercialization by 2028